← All trials
NCT03443830
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 8, 2018
- Primary completion
- Oct 30, 2018
- Completion date
- Dec 31, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Massachusetts Institute of TechnologyLead sponsor
- National University of SingaporeCollaborator
- Duke UniversityCollaborator
- SingHealth Investigational Medicine UnitOverall official - principal investigator
- Singapore Clinical Research InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.